Funder
National Institute of Allergy and Infectious Diseases
Reference35 articles.
1. Anti-tuberculosis treatment strategies and drug development: challenges and priorities;Dartois;Nat Rev Microbiol,2022
2. World health Organization,2022
3. Antibacterial products in clinical development for priority pathogens,2022
4. Heterogeneity in tuberculosis;Cadena;Nat Rev Immunol,2017
5. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses;Lenaerts;Immunol Rev,2015